Procesos de decisión en la antiagregación (IV): Síndrome Coronario Agudo
DOI:
https://doi.org/10.30445/rear.v3i7.459Palabras clave:
antiagregantes, Farmacología, Formación, Medicina preoperatoria, PreanestesiaResumen
El síndrome coronario agudo es la entidad patológica donde los tratamientos de antiagregación o anticoagulación se vuelven más elaborados. Las terapias múltiples, los nuevos antiagregantes y la gran producción científica que genera cambios en las recomendaciones, cambios apoyados por una potente industria farmacéutica, puede complicar la toma de decisiones preoperatorias.
En anteriores entradas hemos hablado sobre la profilaxis primaria de la isquemia cardíaca, y vemos como las recomendaciones sobre su tratamiento preventivo han ido evolucionado para ser cada vez más restrictivas. Los descubrimientos de nuevos factores individuales (tanto genéticos como ambientales) que desempeñen un papel fundamental en la incidencia del síndrome coronario son cada vez más estudiados y aclarados. Desde el descubrimiento de los isotipos del gen de la paraoxonasa-1, pasando por la implicación del perímetro abdominal, hasta llegar a la polución ambiental, se vislumbran con fuerza estos y otros nuevos factores individuales implicados en la aparición de un episodio isquémico coronario, lo que condicionará un cambio de recomendación en las guías futuras para prevenir dichos eventos.
Citas
[1] ISIS-2: (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17.187 cases of suspected acute myocardial infarction: ISIS-2. J Am Coll Cardiol 1988;12(6 Suppl A):3A-13A. [2] Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992;19:671-7 [3] Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H.Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
Van Es RF, Jonker JJ,Verheugt FW, Deckers JW, Grobbee DE. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group.Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13.
Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J 2000;34:168-71.
[4] Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.N Engl J Med 1983;309:396-403.
Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al.Aspirin, sulfinpyrazone, or both in unstable angina. Results of a canadian multicenter trial. N Engl J Med 1985;313:1369-75.
Théroux P, Quimet H, McCans J, Latour JG, Joly P, Levy G, et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-11.
The RISC group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary atery disease. Lancet 1990;226:827-30.
Malhotra S, Sharma YP, Grover A, Majumdar S, Hanif SM, Bhargava VK, et al. Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease. Intern Med J 2003;33:350-4.
[5] Balsano F, Rizzon P,Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al.Antiplatelet treatment with ticlopidine in unstable angina.A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation 1990;82:17-26. [6] CURE:Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-7. [7] CREDO: Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A,Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20. [8] CLASSICS : Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9. [9]STARS: Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al.A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71. [10] FANTASTIC :Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, mmanuelson H et al. Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC)Study. Circulation 1998;98:1597-603. [11]ISAR:Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al.A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084-9. [12] STARC: Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, et al.Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation 1994; 90:2710-5 [13] The GUSTO IV-ACS Investigators: effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized,placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41.
Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000;101:2788-94.
Lincoff AM, Califf RM, Anderson KM,Weisman HF, Aguirre FV, Kleiman NS, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa rceptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 97;30:149-56.
The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revasularization. N Engl J Med 1997;336:1689-96.
The EPISTENT Study Group: randomised placebo-controlled and balloon- angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
Hamm CW, Heeschen C, Goldmann B,Vahanian A,Adgey J, Miguel CM, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999;340:1623-9.
Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94. PRISM Study Investigators. A comparison of aspirin plus tirofi-ban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-505.
PRISM-PLUS Study Investigators. Inhibition of the platelet gly-coprotein IIb-IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISMPLUS) study investigators. N Engl J Med 1998;338:1488-97.
Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms).PRISM-PLUS Investigators. Circulation 1999;100:1609-15.
RESTORE Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban an adverse cardiac events in patientis with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 997;96:1445-53.
Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-28.
The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996;94:899-905.
The PARAGON Trial Investigators. International randomized controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor, heparin or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome eventes in a global organization network. Circulation 1998; 97:2386-95.
[14]Chew DP. Et al. Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa antagonists : A Metaanalisis of Phase III Multicenter Randomizaded Trials. Circulation2001: 103:201-6 [15] Hongo Rh, Ley J, Dick SE,Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-7. [16] Baur HR,VanTassel RA, Pierach CA, Gobel FL. Effects of sulfinpyrazone on early graft closure after myocardial revascularization. Am J Cardiol 1982;49:420-4.
Sanz G, Pajaron A, Alegría E, Coello I, Cardona M, Fournier JA, et al. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Español para el Seguimiento del Injerto Coronario (GESIC). Circulation 1990;82:765-73.
Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation 1989;80:1190-7.
[17] Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988;77:1324-32. [18] Mangano DT, Multicenter Study of Perioperative Ischaemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-17. [19] Colombo A, Neumann FJ et al. Intracoronary stenting without anticoagulation accomplished with intravascular utrsaound guidance . Circulation 1995, 91 (6).1676-88 [20]Popma JJ et al. Antithrombotic therapy during percutaneus coronary intervention. The 7th AAC conference on antithrombotic an thrombotic therapy . Cheste 2004 . 126 3Suppl
Silver S et al . Guidelines for percutaneus Coronay intervention Eur Heart J 2005 : 26 (8)
[21] Iakovou I et al. Incidencia predictors and outcomes of thrombosis after successful implantation of drug-eluting stent . JAMA 2005 . 293 [22] Park DW. Et al . Frecuency of and risk factors for the stent thrombosis after drug-eluting stent implantantion during long term follow-up. Am J Cardiol. 2006 . 98 (3)
Kuchulakanti PK. Et al . Correlates and long term outcomes of angiographically proven stent trombosis with sirolimus-and paclitaxel eluting stents. Circulation 2006. 113 (8)
[23] Watson H, Belcher G, Horrocks M.Adjuvant medical therapy in peripheral bypass surgery. Br J Surg 1999;86:981-91.
Más bibliografía consultada
- PROTOCOLOS DE TRATAMIENTO ANTIAGREGANTES DE LA SEMI (Sociedad Española de Medicina interna), 2.004. Coordinador Demetrio Sánchez Fuentes. Autores José Manuel Barragán Casas, José Luis Hernández Hernández, José Antonio Riancho, Moral, Carmen Suárez Fernández.
- HCSC Protocolo antiagregacion. Dra Durán Giménez- Rico. Dr F Duro Ventura. Dra A.M Muñoz de solano Palacios. Dr Borja San Pedro de Urquiza. Dr Siro Tato. Prof F. Lopez Timoneda. Servicio Anestesiologia Hospital Clínico San Carlos. Madrid. España.
- Valoración Preoperatorio del paciente Antiagregado, portador de Stents Coronario. Dra Angeles de Miguel Guijaro. Servicio Anestesiología H. Gregorio Marañón. Madrid. España. Guía Clínica consensuada.
- Manejo Preoperatorio de la Antiagregación en pacientes portadores de Stent Coronario. P. Sierra. P. Tormas et al. Rev esp anest. 2008. 55 8 (Supl 1).
- James D; ACCP. The perioperative management of antithrombotic therapy. 8TH EDICITION CHEST 2008:133.
- Anticoagulación; Coordinado por Armando Gomez Ortiz MD. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular 2005.
- Hall R, Mazer CD. Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period. Anesth Analg. 2011 Feb;112(2):292-318. Epub 2011 Jan 6.
Van Es RF, Jonker JJ,Verheugt FW, Deckers JW, Grobbee DE. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group.Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13.
Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J 2000;34:168-71.
[4] Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.N Engl J Med 1983;309:396-403.
Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al.Aspirin, sulfinpyrazone, or both in unstable angina. Results of a canadian multicenter trial. N Engl J Med 1985;313:1369-75.
Théroux P, Quimet H, McCans J, Latour JG, Joly P, Levy G, et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-11.
The RISC group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary atery disease. Lancet 1990;226:827-30.
Malhotra S, Sharma YP, Grover A, Majumdar S, Hanif SM, Bhargava VK, et al. Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease. Intern Med J 2003;33:350-4.
[5] Balsano F, Rizzon P,Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al.Antiplatelet treatment with ticlopidine in unstable angina.A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation 1990;82:17-26. [6] CURE:Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-7. [7] CREDO: Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A,Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20. [8] CLASSICS : Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9. [9]STARS: Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al.A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71. [10] FANTASTIC :Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, mmanuelson H et al. Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC)Study. Circulation 1998;98:1597-603. [11]ISAR:Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al.A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084-9. [12] STARC: Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, et al.Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation 1994; 90:2710-5 [13] The GUSTO IV-ACS Investigators: effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized,placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41.
Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000;101:2788-94.
Lincoff AM, Califf RM, Anderson KM,Weisman HF, Aguirre FV, Kleiman NS, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa rceptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 97;30:149-56.
The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revasularization. N Engl J Med 1997;336:1689-96.
The EPISTENT Study Group: randomised placebo-controlled and balloon- angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
Hamm CW, Heeschen C, Goldmann B,Vahanian A,Adgey J, Miguel CM, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999;340:1623-9.
Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94. PRISM Study Investigators. A comparison of aspirin plus tirofi-ban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-505.
PRISM-PLUS Study Investigators. Inhibition of the platelet gly-coprotein IIb-IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISMPLUS) study investigators. N Engl J Med 1998;338:1488-97.
Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms).PRISM-PLUS Investigators. Circulation 1999;100:1609-15.
RESTORE Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban an adverse cardiac events in patientis with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 997;96:1445-53.
Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-28.
The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996;94:899-905.
The PARAGON Trial Investigators. International randomized controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor, heparin or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome eventes in a global organization network. Circulation 1998; 97:2386-95.
[14]Chew DP. Et al. Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa antagonists : A Metaanalisis of Phase III Multicenter Randomizaded Trials. Circulation2001: 103:201-6 [15] Hongo Rh, Ley J, Dick SE,Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-7. [16] Baur HR,VanTassel RA, Pierach CA, Gobel FL. Effects of sulfinpyrazone on early graft closure after myocardial revascularization. Am J Cardiol 1982;49:420-4.
Sanz G, Pajaron A, Alegría E, Coello I, Cardona M, Fournier JA, et al. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Español para el Seguimiento del Injerto Coronario (GESIC). Circulation 1990;82:765-73.
Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation 1989;80:1190-7.
[17] Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988;77:1324-32. [18] Mangano DT, Multicenter Study of Perioperative Ischaemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-17. [19] Colombo A, Neumann FJ et al. Intracoronary stenting without anticoagulation accomplished with intravascular utrsaound guidance . Circulation 1995, 91 (6).1676-88 [20]Popma JJ et al. Antithrombotic therapy during percutaneus coronary intervention. The 7th AAC conference on antithrombotic an thrombotic therapy . Cheste 2004 . 126 3Suppl
Silver S et al . Guidelines for percutaneus Coronay intervention Eur Heart J 2005 : 26 (8)
[21] Iakovou I et al. Incidencia predictors and outcomes of thrombosis after successful implantation of drug-eluting stent . JAMA 2005 . 293 [22] Park DW. Et al . Frecuency of and risk factors for the stent thrombosis after drug-eluting stent implantantion during long term follow-up. Am J Cardiol. 2006 . 98 (3)
Kuchulakanti PK. Et al . Correlates and long term outcomes of angiographically proven stent trombosis with sirolimus-and paclitaxel eluting stents. Circulation 2006. 113 (8)
[23] Watson H, Belcher G, Horrocks M.Adjuvant medical therapy in peripheral bypass surgery. Br J Surg 1999;86:981-91.
Más bibliografía consultada
- PROTOCOLOS DE TRATAMIENTO ANTIAGREGANTES DE LA SEMI (Sociedad Española de Medicina interna), 2.004. Coordinador Demetrio Sánchez Fuentes. Autores José Manuel Barragán Casas, José Luis Hernández Hernández, José Antonio Riancho, Moral, Carmen Suárez Fernández.
- HCSC Protocolo antiagregacion. Dra Durán Giménez- Rico. Dr F Duro Ventura. Dra A.M Muñoz de solano Palacios. Dr Borja San Pedro de Urquiza. Dr Siro Tato. Prof F. Lopez Timoneda. Servicio Anestesiologia Hospital Clínico San Carlos. Madrid. España.
- Valoración Preoperatorio del paciente Antiagregado, portador de Stents Coronario. Dra Angeles de Miguel Guijaro. Servicio Anestesiología H. Gregorio Marañón. Madrid. España. Guía Clínica consensuada.
- Manejo Preoperatorio de la Antiagregación en pacientes portadores de Stent Coronario. P. Sierra. P. Tormas et al. Rev esp anest. 2008. 55 8 (Supl 1).
- James D; ACCP. The perioperative management of antithrombotic therapy. 8TH EDICITION CHEST 2008:133.
- Anticoagulación; Coordinado por Armando Gomez Ortiz MD. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular 2005.
- Hall R, Mazer CD. Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period. Anesth Analg. 2011 Feb;112(2):292-318. Epub 2011 Jan 6.
Publicado
2011-07-31
Cómo citar
Gironés Muriel, A., San Pedro, B., Domenech de Frutos, S., & Lage Piñeiro, S. (2011). Procesos de decisión en la antiagregación (IV): Síndrome Coronario Agudo. Revista Electrónica AnestesiaR, 3(7), 4. https://doi.org/10.30445/rear.v3i7.459
Número
Sección
Artículos de revisión
Revista Electrónica AnestesiaR by 